NEW DELHI : Bharat Biotech International would face a delay in introducing its covid-19 vaccine Covaxin into the United States after USFDA’s rejection for its emergency use authorisation (EUA).Amidst several doubts over its safety and efficacy, the Hyderabad based pharmaceutical company on Friday came into defence of covaxin-- India’s first indigenous covid-19 vaccine—stating that covaxin has received EUA’s from 14 countries with more than 50 countries in the process.“Our US partner, Ocugen has received a recommendation from the FDA to pursue Biologics License Applications (BLA) path for covaxin, which is full approval.